A large UK study found that serious muscle disorders linked to statin treatment are rare. Learn how a new prediction model may improve personalized treatment decisions.
Statins are among the most commonly prescribed medications for lowering cholesterol and reducing the risk of heart attack and stroke. Although these medicines have been shown to save lives, concerns about muscle related side effects often discourage people from starting or continuing treatment.
A new large scale study from England has introduced a clinical prediction model that estimates an individual's risk of developing serious muscle disorders while being eligible for statin therapy. The findings suggest that severe muscle complications are uncommon for most people and that personalized risk assessments could support better conversations between patients and healthcare professionals.
Many people have heard that statins can cause muscle pain or weakness. While mild muscle symptoms are relatively common, research has shown that they are often not directly caused by statins. In contrast, serious muscle disorders, such as rhabdomyolysis, are rare but can require hospitalization and immediate medical care.
Because fears about muscle problems frequently lead people to stop taking statins, researchers wanted to develop a tool that could estimate an individual's actual risk instead of relying on broad population averages.
Researchers analyzed electronic health records from the Clinical Practice Research Datalink in England. The study included more than 1.78 million people to develop the prediction model and another 3.89 million individuals to test its accuracy.
Eligible participants included men aged 50 years and older and women aged 60 years and older who were considered potential candidates for statin treatment. Both current statin users and individuals who had not yet started treatment were included.
The researchers followed participants for up to 10 years and recorded serious muscle disorders that resulted in hospitalization or death. They also considered deaths from unrelated causes to improve the accuracy of the prediction model.
One of the most important findings is that the overall risk of serious muscle disorders is extremely low.
Nearly 99.6 percent of people in the validation group had a predicted 10 year risk below 10 percent. In fact, the actual occurrence of serious muscle disorders over 10 years was only about 0.44 to 0.45 percent.
The prediction model also performed well when tested in an independent population. It accurately identified individuals who were more likely to experience serious muscle complications while maintaining reliable calibration across different risk groups.
These findings suggest that personalized risk prediction could become a valuable addition to existing cardiovascular risk assessments.
The researchers identified 22 clinical factors that influence a person's likelihood of developing serious muscle disorders.
Some of the strongest predictors included:
Because these factors are commonly recorded during routine healthcare visits, the model could be incorporated into everyday clinical practice without requiring specialized testing.
Previous prediction models often focused on muscle pain and other mild symptoms that may not actually be caused by statins. This new study concentrated on serious muscle disorders that have genuine clinical importance.
Another strength is the enormous sample size. By analyzing health records from more than 5.6 million people, researchers were able to build and validate a model with strong predictive performance.
The model also predicts risk over 1 year, 5 years, and 10 years, allowing healthcare professionals to compare muscle disorder risk with long term cardiovascular risk when discussing treatment options.
One of the biggest barriers to statin use is concern about side effects. Many patients stop taking their medication because they worry about muscle problems, even when their cardiovascular risk is high.
A personalized prediction model can help address these concerns by providing an estimate based on an individual's own medical history rather than general statistics.
For patients with a very low predicted risk of serious muscle disorders, the information may provide reassurance that the benefits of statins are likely to outweigh the potential harms.
For people identified as having a higher risk, healthcare providers may decide to monitor muscle symptoms more closely, check for underlying conditions, review other medications, or consider alternative cholesterol lowering treatments when appropriate.
Although the model showed strong performance, the researchers acknowledged several limitations.
Some important risk factors, including genetics and physical activity, were not available in the healthcare records and therefore could not be included in the analysis.
The model was also developed using healthcare data from England. While the findings are highly relevant to UK clinical practice, additional validation is needed before applying the model to populations in other countries.
Finally, because serious muscle disorders are rare, even individuals classified as higher risk are still unlikely to experience these complications.
The study reinforces an important message. Serious muscle complications associated with statins are uncommon for most eligible patients.
Instead of making treatment decisions based solely on fear of potential side effects, patients and healthcare professionals can benefit from personalized risk estimates that consider both the benefits and the possible risks of therapy.
As precision medicine continues to evolve, tools like this prediction model could make conversations about statins more balanced, informed, and tailored to each individual's health profile.
Statins remain one of the most effective treatments for preventing cardiovascular disease, yet concerns about muscle side effects continue to affect treatment decisions. This new research provides evidence that serious muscle disorders are rare and that individualized risk prediction can support more informed choices.
By combining cardiovascular risk assessment with personalized estimates of serious muscle disorder risk, healthcare providers may be able to improve shared decision making, increase appropriate statin use, and help more patients benefit from long term protection against heart disease.
Cai T, Hirst JA, Nicholson BD, McManus RJ, Hobbs FDR, Sheppard JP, et al. Predicting the risk of serious muscle disorders in individuals eligible for statin treatment in England: Derivation and validation of a clinical prediction model. Published online in The Lancet, June 25, 2026.
This article is intended for informational and educational purposes only. It should not be considered medical advice or used as a substitute for professional healthcare guidance. Always consult a qualified healthcare provider before starting, stopping, or changing any medication, including statins. Individual treatment decisions should be based on a person's medical history, overall cardiovascular risk, and clinical evaluation.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.